{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"16.7","value":"5.7"},{"groupId":"OG002","lowerLimit":"3.7","upperLimit":"16.7","value":"5.7"},{"groupId":"OG003","lowerLimit":"3.7","upperLimit":"16.7","value":"5.7"},{"groupId":"OG004","lowerLimit":"3.7","upperLimit":"16.7","value":"5.7"}]}],"title":"Progression Free Survival/PFS"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"10.0","upperLimit":"48.8","value":"24.0"},{"groupId":"OG002","lowerLimit":"10.0","upperLimit":"48.8","value":"24.0"},{"groupId":"OG003","lowerLimit":"10.0","upperLimit":"48.8","value":"24.0"},{"groupId":"OG004","lowerLimit":"10.0","upperLimit":"48.8","value":"24.0"}]}],"title":"Overall Survival/OS"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"26.2","value":"15.7"},{"groupId":"OG002","lowerLimit":"4.1","upperLimit":"26.2","value":"15.7"},{"groupId":"OG003","lowerLimit":"4.1","upperLimit":"26.2","value":"15.7"},{"groupId":"OG004","lowerLimit":"4.1","upperLimit":"26.2","value":"15.7"}]}],"title":"Duration of Response/DOR"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"1.9","upperLimit":"9.0","value":"3.7"},{"groupId":"OG002","lowerLimit":"1.9","upperLimit":"9.0","value":"3.7"},{"groupId":"OG003","lowerLimit":"1.9","upperLimit":"9.0","value":"3.7"},{"groupId":"OG004","lowerLimit":"1.9","upperLimit":"9.0","value":"3.7"}]}],"title":"Time To Best Response/TTBR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"36"}],"units":"Participants"}],"description":"Duration of response (DOR), and event free survival (EFS). Time to response,duration of response and event free survival will be analyzed by routine survival analysis tools such as Kaplan-Meier estimation or competing risks method. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions","dispersionType":"95% Confidence Interval","groups":[{"description":"Romidepsin 8 mg/m\\^2/Lenalidomide 10 mg","id":"OG000","title":"Dose Level -1"},{"description":"Romidepsin 8 mg/m\\^2/Lenalidomide 15 mg","id":"OG001","title":"Dose Level 1"},{"description":"Romidepsin 8 mg/m\\^2/Lenalidomide 25 mg","id":"OG002","title":"Dose Level 2"},{"description":"Romidepsin 10 mg/m\\^2/Lenalidomide 25 mg","id":"OG003","title":"Dose Level 3"},{"description":"Romidepsin 14 mg/m\\^2/Lenalidomide 25 mg","id":"OG004","title":"Dose Level 4"}],"paramType":"MEDIAN","populationDescription":"No participants treated on Dose Level -1","reportingStatus":"POSTED","timeFrame":"up to 50 months","title":"Assess the Time to Best Response (TTBR)","type":"SECONDARY","unitOfMeasure":"months"}